✓ Medically reviewed by  ·  Last reviewed: May 2026

Morgan Ellis

Pharmacy Researcher · 8 years experience

Pharmacy researcher with 8 years reviewing clinical drug information, generic formulation equivalence, and international pharmaceutical standards. Focuses on patient-facing accuracy in medication education.

If you searched for “Ozempic alternatives” you are almost certainly in one of two situations: you cannot get hold of Ozempic where you live, or you can get it but the cost or side-effect profile is a problem. Either way, the practical question is the same — which other medicines actually drive weight loss, and how do they compare to a GLP-1 like Ozempic in mechanism, expected weight loss, side effects, and price? This guide walks through the 10 best Ozempic alternatives available in 2026, grouped by drug class so you can match your situation to the right option. Some are direct GLP-1 / multi-agonist peptide alternatives. Others are oral tablet classes (lipase inhibitors, SGLT-2 inhibitors, dual PPAR agonists, herbal blends) with very different mechanisms but a real role in weight management.

Best Ozempic Alternatives (2026): 10 Weight-Loss Medications Compared

Last updated: May 13, 2026 · Reviewed by the MedsBase Medical Team

How Ozempic Works — and What “Alternative” Actually Means

Ozempic’s active ingredient is semaglutide, a long-acting GLP-1 receptor agonist — the same molecule we stock as a research-grade injectable peptide. GLP-1 (glucagon-like peptide-1) is a gut hormone that does three things relevant to weight loss: it slows gastric emptying so you feel full longer, it acts in the brain on appetite-control centres to reduce food cravings, and it boosts insulin release in response to meals (which is why it was originally developed for type-2 diabetes). The same mechanism is used by tirzepatide (Mounjaro / Zepbound), liraglutide (Victoza / Saxenda) and the newest triple agonist retatrutide. See our GLP-1 weight-loss injections guide for a deeper comparison of all three.

When people search “Ozempic alternatives” they usually mean one of three things:

1. A direct mechanistic alternative — another GLP-1 or multi-agonist peptide that hits the same receptors. The closest example currently available is retatrutide, which adds GIP and glucagon receptor agonism on top of GLP-1 for the highest reported weight-loss effect of any obesity drug.

2. A different drug class with weight-loss effect — orlistat (lipase inhibitor), SGLT-2 inhibitors (glucose-driven calorie loss), dual PPAR agonists like saroglitazar (lipid + weight + liver fat). Different mechanism, oral tablet format, lower cost per month, milder peak effect.

3. An adjunct or natural option — herbal formulations like AyurSlim that support appetite and metabolism without acting on hormonal pathways. Best framed as a complement to lifestyle change, not a replacement for a prescription weight-loss drug.

This guide covers all three. The comparison table further down maps each pick to mechanism, expected weight loss, format, and best-fit profile.

The 10 Best Ozempic Alternatives — Reviewed

The picks below cover one direct peptide alternative, four orlistat brands (different makers, same molecule and dose), three SGLT-2 inhibitors, one dual PPAR agonist, and one herbal option. Each entry tells you what it is, who it is for, and the practical trade-offs.

1. Retatrutide — Closest Direct Alternative to Ozempic (Triple Agonist)

Retatrutide is a once-weekly subcutaneous injectable peptide that activates three incretin and counter-regulatory receptors at once: GLP-1 (the same receptor Ozempic targets), GIP (the second receptor that tirzepatide adds), and glucagon (the third axis, which boosts energy expenditure). The 48-week phase 2 obesity trial reported up to ~24% body-weight loss at the highest dose, the largest figure published for any obesity pharmacotherapy.

This is the right pick if your goal is the same magnitude of weight loss as Ozempic or higher, you are comfortable with a once-weekly subcutaneous injection, and you want the most aggressive mechanism currently available. Note that retatrutide is still in late-stage trials regulatory-wise — it is available here as a research peptide. Same broad GI side-effect profile as Ozempic (nausea, slow gastric emptying) at the dose-titration phase.

2. Orlijohn — Best Branded Orlistat (120 mg, Pharma-Grade)

Orlijohn contains 120 mg of orlistat — a gastric and pancreatic lipase inhibitor that blocks the absorption of roughly 30% of dietary fat from each meal. The unabsorbed fat passes through the GI tract and is excreted, producing a small but consistent calorie deficit. Trials show 5–10% weight loss over 12 months when paired with a calorie-controlled diet — meaningfully less than a GLP-1 but with no hormonal mechanism, no injection, and a long established safety record.

Orlistat is the right pick if you want an oral tablet (no injection), have a moderate weight-loss target (5–10% of body weight rather than 15–25%), and prefer a non-hormonal mechanism. Take with each main meal that contains fat. The headline trade-off is GI side effects — oily stools, urgency, flatulence with discharge — all of which are dose-dependent on the fat content of meals. Eat less fat, fewer side effects.

3. Slimtop — Reliable Orlistat Generic

Slimtop contains the same 120 mg orlistat as Orlijohn, manufactured to WHO-GMP pharmacopeial standards by a different generic maker. Pharmacologically the two are interchangeable. The choice between Slimtop and Orlijohn comes down to brand availability and price per pack, not clinical effect.

Pick Slimtop when you want a known orlistat generic at a typical mid-range price point. Same dose schedule (one capsule with each fat-containing main meal, up to three per day), same fat-blocking mechanism, same side-effect profile.

4. Vyfat — Budget Orlistat Option

Vyfat is Intas Pharmaceuticals’ orlistat brand — typically the lowest-priced 120 mg orlistat in our catalogue. Same molecule, same dose, same WHO-GMP standard as Orlijohn and Slimtop. The differentiator is purely commercial.

Choose Vyfat when cost per dose is the primary constraint and you want to stock several months of daily use. Orlistat is one of the most thoroughly studied weight-loss drugs in history (>20 years of post-marketing data), so the budget-vs-premium choice is purely about price, not safety or effect.

5. Obelit — Obesity-Branded Orlistat

Obelit rounds out the orlistat range as another generic 120 mg option. We list four orlistat brands because demand for non-injectable, low-side-effect-profile alternatives to GLP-1 drugs is high, and brand availability fluctuates per ship-to country — having multiple WHO-GMP-equivalent options means we rarely have to redirect a customer to a different molecule entirely.

If your existing orlistat supplier ships Obelit and you have used it before, stay with what works. If you are new to orlistat, the four brands are clinically interchangeable — pick on price.

6. AyurSlim Capsule — Best Herbal Adjunct

AyurSlim Capsule from Himalaya Wellness is a multi-herb Ayurvedic formulation (Garcinia, Gymnema, Indian Bdellium and others) with claims around appetite regulation and lipid metabolism. The expected effect size is small — a few kilograms of weight loss over months — and the evidence base is much thinner than for the prescription options above.

This is the right pick if (a) you want a non-prescription, non-pharmaceutical adjunct to a structured diet-and-exercise programme, (b) you have ruled out hormonal causes of weight gain (thyroid, PCOS, low testosterone), and (c) you are not expecting GLP-1-magnitude effects. Frame AyurSlim as a complement to lifestyle change, not as a replacement for a prescription weight-loss drug.

7. Forxiga (Dapagliflozin) — Best SGLT-2 Inhibitor for Type-2 Diabetes With Weight Loss

Forxiga (dapagliflozin) is an SGLT-2 inhibitor that blocks glucose reabsorption in the kidney, causing several hundred kcal of glucose to be excreted in urine each day. The clinical effects are: HbA1c drops 0.6–0.9%, body weight drops 2–3 kg over 24 weeks, blood pressure drops a few mm Hg, and (most importantly in modern guidelines) cardiovascular and renal events are reduced independently of glucose lowering.

This is the right pick when type-2 diabetes is part of the picture and you want a single oral tablet that hits glucose, weight, blood pressure, and cardio-renal risk together. The weight-loss magnitude is modest compared to Ozempic, but the cardio-renal outcome data is strong enough that current diabetes guidelines often place SGLT-2 inhibitors alongside GLP-1 agonists as preferred first-line add-ons after metformin.

8. Jardiance (Empagliflozin) — Strongest Cardio-Renal Outcome Data

Jardiance (empagliflozin) is the SGLT-2 inhibitor with the strongest published cardio-renal outcome data — EMPA-REG OUTCOME, EMPEROR-Reduced and EMPEROR-Preserved — covering type-2 diabetes, heart failure with reduced ejection fraction, and heart failure with preserved ejection fraction. Weight-loss effect is similar to Forxiga (~2–3 kg over 6 months); the differentiator is the breadth of indication.

Pick Jardiance when you have type-2 diabetes plus heart failure or chronic kidney disease, or when your priority is the most-studied SGLT-2 inhibitor for cardio-renal protection. Same caveat as Forxiga — the weight-loss magnitude is modest compared to GLP-1 drugs.

9. Invokana (Canagliflozin) — Renal-Outcome SGLT-2 Inhibitor

Invokana (canagliflozin) is the third major SGLT-2 inhibitor, with the CREDENCE renal-outcome trial showing a significant reduction in progression to end-stage kidney disease in patients with type-2 diabetes and existing diabetic kidney disease. Weight-loss effect is in the same 2–3 kg range as the other two SGLT-2 inhibitors.

Choose Invokana when type-2 diabetic kidney disease is part of the clinical picture and you want the SGLT-2 inhibitor with the strongest renal-progression data. The Box warning for amputation risk seen in the original CANVAS programme has been moderated in subsequent labelling, but it is still worth being aware of in patients with peripheral arterial disease.

10. Lipaglyn (Saroglitazar) — Dual PPAR Agonist for Metabolic Syndrome

Lipaglyn (saroglitazar) is a dual PPAR α/γ agonist developed for the cluster of patients with diabetic dyslipidaemia, NAFLD/NASH, or metabolic syndrome — situations where elevated triglycerides, insulin resistance, fatty liver, and weight-gain trajectory all need to be addressed together. Trials show modest weight reduction alongside meaningful drops in triglycerides, ALT/AST, and liver fat fraction.

Pick Lipaglyn when the patient is not just overweight but is in the metabolic-syndrome / NAFLD overlap zone, or when triglyceride and liver-enzyme reduction is as important as the weight number. Not a first-line obesity drug — but in the right metabolic-syndrome profile, the multi-target effect can be the right tool.

At-a-Glance Comparison Table

This is the centrepiece of the guide. Use this table to match your priority — peptide vs oral, magnitude of weight loss, type-2-diabetic status, side-effect tolerance — to the right pick.

Browse the full catalogue on the weight-loss medication category page, or see related guides in our GLP-1 weight-loss injections guide and tirzepatide vs semaglutide comparison.

How to Choose the Right Alternative

The single most useful question to ask yourself is “how much weight do I want to lose, and am I open to a weekly injection?” Everything else flows from that.

A common mistake is treating “Ozempic alternative” as a single category. The five drug classes above achieve weight loss through entirely different pathways and have entirely different best-fit profiles. Retatrutide is what to reach for if you want GLP-1-class results without the supply / price problem on Ozempic; orlistat is what to reach for if you want an oral non-hormonal option; SGLT-2 inhibitors are right when type-2 diabetes is part of the picture; saroglitazar is right when metabolic-syndrome lipid abnormalities are co-driving the problem; AyurSlim is right when you are looking for a non-prescription adjunct to lifestyle change.

Side Effects, Interactions & Safety

Each drug class has a distinct safety profile. The brief version:

GLP-1 / multi-agonist peptides (Retatrutide): nausea, vomiting, diarrhoea, and slow gastric emptying are common during dose titration and usually settle. Pancreatitis is the rare-but-important risk to know. Not for use in pregnancy or in people with personal or family history of medullary thyroid carcinoma.

Orlistat (Orlijohn / Slimtop / Vyfat / Obelit): the side-effect profile is GI and dose-dependent on the fat content of meals — oily stools, faecal urgency, flatulence with discharge. A daily multivitamin (taken at bedtime, away from orlistat dosing) compensates for reduced fat-soluble vitamin absorption. Rare hepatic events have been reported.

SGLT-2 inhibitors (Forxiga / Jardiance / Invokana): the predictable side effects are genital mycotic infections (mechanism: glycosuria), increased urination, volume depletion / hypotension in patients on diuretics, and a small risk of euglycaemic diabetic ketoacidosis especially around surgery, low-carb diets, or acute illness. Stop temporarily during acute illness and around surgery. Invokana carries a historical caution about amputation risk in patients with peripheral arterial disease.

Saroglitazar (Lipaglyn): generally well-tolerated. Monitor liver enzymes — these usually drop on therapy as NAFLD improves, but baseline LFTs are sensible.

AyurSlim: generally well-tolerated in published case series. Multi-herb formulations carry the usual caveats around drug interactions; if you are on warfarin, anti-platelet drugs, or multiple prescription medications, check for documented herb-drug interactions before stacking.

Frequently Asked Questions

What is the most effective Ozempic alternative?

Retatrutide is the most effective alternative by absolute weight loss — its phase 2 obesity trial reported up to ~24% body-weight loss at 48 weeks at the highest dose, the largest figure published for any obesity drug. The trade-off is that it is a once-weekly subcutaneous injection (not an oral pill) and it is still in late-stage trials regulatory-wise.

Are there oral pill alternatives to Ozempic?

Yes — orlistat brands (Orlijohn, Slimtop, Vyfat, Obelit) are the most widely-used oral weight-loss tablets. Expect 5–10% weight loss over 12 months when paired with a calorie-controlled diet, versus 15–25% for injectable GLP-1 / multi-agonist peptides. SGLT-2 inhibitors (Forxiga, Jardiance, Invokana) are oral tablets that produce 2–3 kg weight loss alongside their primary glucose-lowering effect; they are particularly useful when type-2 diabetes is part of the picture.

How does retatrutide compare to Ozempic?

Retatrutide hits three receptors (GLP-1, GIP, glucagon); semaglutide (Ozempic) hits one (GLP-1). The clinical translation is substantially higher peak weight loss in trials — roughly 17–24% body-weight loss at 48 weeks for retatrutide vs ~15% for semaglutide. The side-effect profile is broadly similar (GI symptoms during titration). See our retatrutide guide and tirzepatide product page for the full breakdown.

Can I take orlistat without a prescription?

Lower-dose orlistat (60 mg) is available without a prescription as Alli in many markets; the 120 mg prescription strength is what is stocked here as Orlijohn / Slimtop / Vyfat / Obelit. The 120 mg dose has roughly twice the fat-blocking effect of the 60 mg version. Still take it with a calorie-controlled, fat-moderate diet — eat a high-fat meal and the GI side effects scale with it.

Do SGLT-2 inhibitors cause weight loss without diabetes?

SGLT-2 inhibitors do produce a small amount of weight loss in non-diabetics (1–2 kg over months) but the effect is much weaker without elevated blood glucose to drive glucosuria. They are not first-line obesity drugs in non-diabetics — the evidence base and licensing are firmly in the type-2 diabetes / heart failure / CKD setting.

What is the difference between the four orlistat brands?

Orlijohn, Slimtop, Vyfat and Obelit all contain the same active ingredient (orlistat 120 mg) at the same dose, manufactured to WHO-GMP pharmacopeial standards by different generic makers. The clinical effect is identical; the differences are commercial — pack size, price, regional brand familiarity. Pick on price or on which brand your existing supplier ships reliably.

Can I combine orlistat with a GLP-1 like retatrutide?

There is no documented pharmacological interaction between orlistat (a GI lipase inhibitor that does not enter systemic circulation in meaningful amounts) and GLP-1 / multi-agonist peptides. The two mechanisms are complementary on paper — orlistat blocks fat absorption at the meal, GLP-1 reduces appetite and slows gastric emptying — but the additive evidence in trials is limited. Most clinicians pick one and optimise it before stacking.

How fast will I see weight loss on these alternatives?

Retatrutide produces visible appetite reduction within 1–2 weeks; meaningful weight loss accrues over 12–24 weeks of dose titration. Orlistat shows effect within the first month if compliance with diet is good. SGLT-2 inhibitors show their 2–3 kg weight reduction over the first 12–24 weeks. Lipaglyn’s effect on weight is slower and most visible in the metabolic-syndrome / NAFLD subgroup over 6–12 months. Herbal adjuncts like AyurSlim are inherently slow — judge over 3–6 months.

Where can I buy these Ozempic alternatives?

All ten products on this list are available on this site. Click through any of the brand links above to the relevant product page, or browse the full weight-loss medication category. Worldwide shipping.

The Bottom Line

There is no perfect drop-in replacement for Ozempic. There is the best alternative for your situation. If your priority is matching or beating Ozempic-magnitude weight loss and you are open to a weekly injection, Retatrutide is the closest direct alternative available right now — or pick Semaglutide (the actual Ozempic / Wegovy molecule, ~15% loss) or Tirzepatide (Mounjaro / Zepbound, ~15–22% loss) for the directly-equivalent molecules at the dose ranges most people are looking for. If you want an oral, non-hormonal route with a modest target, Orlijohn or Vyfat (orlistat 120 mg) are the most reliable picks. If type-2 diabetes is part of the picture, an SGLT-2 inhibitor (Forxiga / Jardiance / Invokana) is the more elegant single-drug answer than stacking metformin + a GLP-1. Match your situation to the right class first; pick the brand inside that class on price.

Written by

Sophie Chen

Pharmaceutical Content Researcher · 8 years experience

Sophie Chen is a pharmaceutical content researcher with 8 years covering generic medication access and clinical pharmacology. She specialises in international regulatory frameworks, bioequivalence standards, and patient-facing education on therapeutic drug classes. She is not a clinician.